BioSpace News Archive

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2020 and provided an update on recent corporate developments. “We continued to make meaningful progress throughout the first quarter across all of our promising DNAbilize

BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced companywide activities in support of hae day :-) 2020, a global awareness day for hereditary angioedema (HAE). BioCryst stands in solidarity with the HAE community by participating in the annual HAE Global Walk. Since actual community walks cannot currently be organized, BioCryst employees around the world are joining virtually with others supporting hae day :-) b

Abstracts feature data on ETBs against clinically validated targets including PD-L1, CTLA-4, SLAMF7 and CD45

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced that it had received the CE mark approval for AlloSeq Tx 17, making it broadly available to transplant patients, laboratories and clinicians around the world. AlloSeq Tx 17 is the best in class so

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced financial results for the first quarter ended March 31, 2020, and highlighted recent corporate accomplishments.

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended March 31, 2020 on Wednesday, May 20, 2020 , before

Significant inhibition of vasculogenic mimicry observed with TH1902 and TH1904 New peptide-curcumin conjugate, TH1901, shows 100 times greater anti-cancer cell proliferation activity than unconjugated curcumin in vitro Results to be presented at American Association for Cancer Research (AACR) Virtual Annual Meeting II MONTREAL, May 15, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today

Data support the initiation of an upcoming first-in-human trial for first-line, MRD+ multiple myeloma patients post-ASCT

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today reported financial results for the three months ended March 31, 2020 and provided a business update. “Despite the challenges caused by the emerging COVID-19 pandemic, we continued to make significant progress to advance the development of our lead compound,

GeorgiaALIVE Inc., a leadership initiative for a vital economy, unveils the GeorgiaALIVE Exchange, a marketplace of regional services and resources relating to the COVID-19 response for both organizations and individuals.